Featured article
ESR1 Mutations and Endocrine Resistance in Advanced Breast Cancer
For patients with ER-positive, HER2-negative advanced or metastatic breast cancer, reassessing tumor biology after progression can reveal changes that influence the next clinical discussion.
Read article